Our centre is based in the largest public hospital in Italy (the “Città della Salute e della Scienza” hospital of Torino). We follow about 350 patients each year, both locally and nationwide. We have a diagnostic laboratory and a molecular genetics laboratory. Our scientific studies include both clinical and basic research of ALS. In the last decade, we have participated in 5 large international randomized clinical trials on innovative drugs in ALS. We have a multidisciplinary group and a daily ALS clinic. We also provide psychological, neuropsychological and neurophysiological services.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.